Standout Papers

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One <... 2023 2026 202465
  1. Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele (2023)
    Jennifer L. Goralski, Jordana E. Hoppe et al. American Journal of Respiratory and Critical Care Medicine

Immediate Impact

3 from Science/Nature 60 standout
Sub-graph 1 of 23

Citing Papers

Gold Recovery from E‐Waste by Food‐Waste Amyloid Aerogels
2024 Standout
Cystic fibrosis
2024 Standout
1 intermediate paper

Works of Mengdi Lu being referenced

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One F508del Allele
2023 Standout
Hybridization conditions of oligonucleotide-capped gold nanoparticles for SPR sensing of microRNA
2018

Author Peers

Author Last Decade Papers Cites
Mengdi Lu 502 294 211 402 55 943
Marta Duch 396 148 68 295 51 800
Anne Charrier 389 242 61 338 49 1.2k
Chen-Han Huang 567 528 186 265 35 1.1k
Markéta Bocková 685 567 232 279 39 1.1k
Văn Hiếu Nguyễn 419 125 161 517 45 1.0k
G.A.J. Besselink 768 366 41 373 33 1.1k
Ilaria Mannelli 507 494 90 171 29 895
Jörg Opitz 378 169 64 244 71 968
Yan Wang 287 241 120 177 41 811
Fabio Domenici 524 260 209 85 70 970

All Works

Loading papers...

Rankless by CCL
2026